局部切除后辅助接触X线近距离放疗在多中心直肠癌患者中的分析:CONTEM1研究初步结果
该多中心回顾性分析纳入2004至2017年间三家中心局部切除后接受辅助接触X线近距离放疗(CXB)的194例早期直肠癌患者,所有患者均存在不良病理特征。中位随访77个月,局部复发率8%,远处转移率9%,保器官率95%,6年局部无复发生存率91%、总生存率81%、癌症特异性生存率97%,无治疗相关死亡。提示辅助CXB可作为选择合适患者避免完成全直肠系膜切除术的替代方案。
要点
- 局部切除后辅助CXB的6年局部无复发生存率91%,总生存率81%。
- 保器官率达95%,局部复发率8%,远处转移率9%,无治疗相关死亡。
- 该方案可作为选择性患者避免完成TME的替代选择,需长期随访。
核心结论
- 局部切除后辅助CXB在这组具有不良病理特征的患者中显示良好的肿瘤学结局,可考虑作为选择性患者的替代治疗。
研究设计与样本
- 多中心回顾性队列研究,纳入2004至2017年间三家中心局部切除后接受辅助CXB的194例直肠癌患者。
- 所有患者均具有不良病理特征,包括淋巴血管侵犯、Sm2-3 Kikuchi分级、肿瘤出芽、pT2、切缘阳性(R1)。
- CXB使用Papillon50机器,剂量40-60 Gy分2或3次,在体外放化疗前后2-4周内完成;采用Kaplan-Meier法评估生存结局。
主要发现
- 中位年龄70岁,pT分期为pT1 143例、pT2 45例、pT3 6例;24例仅接受CXB,170例联合EBRT。
- 中位随访77个月(范围7-122个月),局部复发率8%,远处转移率9%,保器官率95%。
- 6年局部无复发生存率91%,总生存率81%,癌症特异性生存率97%,无治疗相关死亡。
关键数值与推荐
- CXB剂量为40-60 Gy分2或3次,在体外放化疗前后2-4周内进行。
- 不良病理特征包括淋巴血管侵犯、Sm2-3 Kikuchi分级、肿瘤出芽、pT2、切缘阳性(R1)。
临床怎么用
- 对于局部切除后具有不良病理特征但不适合或拒绝完成TME的患者,辅助CXB可作为保器官的替代方案。
- 治疗决策需结合患者对长期随访的依从性进行选择。
局限性
- 本研究为回顾性多中心分析,仅为初步结果,可能存在选择偏倚。
- 随访时间范围较宽(7-122个月),部分患者随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Early rectal cancers are increasingly diagnosed through screening programmes and are often treated using local excision (LE). In the case of adverse pathological features completion total mesorectal excision surgery (TME) is the standard recommendation. The morbidity and mortality risks of TME have stimulated the use of adjunctive treatments following LE to achieve organ preservation. MATERIAL AND METHODS: Patients treated with adjuvant CXB following local excision between 2004 and 2017 in three centres were identified (Clatterbridge, Hull, Nice). All patients had adverse pathological features including: lymphovacular invasion, Sm2-3 Kikuchi level, tumour budding, pT2, positive resection margins (R1). CXB was performed with the Papillon50 tm machine to a dose of 40-60 Gy in 2 or 3 fractions over 2-4 weeks preceding/following external beam chemo/radiotherapy. Kaplan Meier survival estimates were used for outcomes measures. RESULTS: 194 patients were identified. Median age was 70 years. pT staging was: pT1:143, pT2:45, pT3:6. CXB alone was given in 24 pts and combined with EBRT in 170. Median follow-up time was 77 months (range 7-122 months). Local relapse rate was 8% and distant metastases 9%. Organ preservation was achieved in 95%. 6 year local recurrence free and overall survival was 91% and 81% respectively. Cancer specific survival was 97%. No treatment related mortality was seen. CONCLUSION: This large multi-centre cohort study using adjuvant CXB following local excision suggests excellent oncological outcomes for these patients without completion TME. This treatment approach can be considered as an alternative for selective patients compliant with long term follow up.
引用
- Dhadda A, Sun Myint A, Thamphya B, et al. A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision - Preliminary results of the CONTEM1 study. Radiother Oncol. 2021. PMID: 34329654. doi:10.1016/j.radonc.2021.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。